Adherence to treatment guidelines in Type 2 diabetes patients failing metformin monotherapy in a real-world setting

Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review

“…Out of 7698 combined search results, 53 articles were identified that reported at least 1 measure of therapeutic inertia in the management of hyperglycaemia in individuals with type 2 diabetes . The main reasons for exclusion of publications other than duplicates and those covering irrelevant topics were that they reported non‐original research (eg, editorials, letters, comments and guidelines) or they were congress abstracts (Figure ).…”

“…The majority of studies were conducted in North America (29 studies) and Europe (20 studies). Three studies were carried out in Asia, and a single study was conducted in Israel . Articles mainly reported data from cohort studies, using data from medical records or chart reviews, or from claims, clinical research or administrative databases.…”

“…Three studies were carried out in Asia, and a single study was conducted in Israel . Articles mainly reported data from cohort studies, using data from medical records or chart reviews, or from claims, clinical research or administrative databases. Four articles reported results from cross‐sectional studies, and the data were collected using provider questionnaires or surveys .…”

“…Patients were managed by primary care providers in 21 studies, by both primary care providers and secondary care specialists in 6 studies, and by secondary care specialists alone in 1 study . The healthcare providers responsible for patient care were not described in 25 studies . Treatment characteristics varied across studies.…”

Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study

“…The current study therefore aimed to compare urinary albumin excretion levels among T2DM patients treated with sitagliptin as add on to metformin in comparison to patients treated with another common potent anti-diabetic therapy, sulfonylurea (SU) 11 . Our hypothesis was that the reduction in proteinuria will be larger in sitagliptin-treated patients compared with patients receiving sulfonylurea since studies with DPP-4 inhibitors suggest a potential reno-protective effect beyond glucose-lowering.…”